Gunther Nussbaumer

Gunther Nussbaumer

Auto-generated profile, based on publicly available information

Gunther Nussbaumer

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
GNGunther Nussbaumer
Gunther Nussbaumer
MBMartin Benesch
Martin Benesch
Beckwith–Wiedemann spectrum, Simpson–Golabi–Behmel syndrome, familial adenomatous polyposis and trisomy 18 are the most common congenital conditions associated with an increased incidence of hepatoblastoma (HB). In patients with these genetic disorders, screening protocols for HB are proposed that include periodic abdominal ultrasound and measurement of alpha‐fetoprotein levels. Surveillance in these children may contribute to the early detection of HB and possibly improve their chances of overall survival. Therefore, physicians must be aware of the high HB incidence in children with certain predisposing genetic diseases.

8 May 2024 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
GNGunther Nussbaumer
Gunther Nussbaumer
MBMartin Benesch
Martin Benesch
YGYura Grabovska
Yura Grabovska
AMAlan Mackay
Alan Mackay
DCDavid Castel
David Castel
CKChristof Maria Kramm
Christof Maria Kramm
The term Gliomatosis cerebri (GC), a radiology-defined highly infiltrating diffuse glioma, has been abandoned since molecular GC-associated features have not been established yet. We conducted a multinational retrospective study of 104 children and adolescents with GC providing comprehensive clinical and (epi-)genetic characterization. Median overall survival (OS) was 15.5 months (interquartile range, 10.9–27.7) with a 2-years survival rate of 28%. Histopathological grading correlated significantly with median OS: CNS WHO grade II: 47.8 months (25.2–55.7); grade III: 15.9 months (11.4–26.3); grade IV: 10.4 months (8.8–14.4). By DNA methylation profiling (n=49), most tumors were classified as pediatric-type diffuse high-grade glioma (pedHGG), H3-/IDH-wildtype (n=31/49, 63.3%) with enriched subclasses pedHGG_RTK2 (n=19), pedHGG_A/B (n=6), and pedHGG_MYCN (n=5), but only one pedHGG_RTK1 case. Within the pedHGG, H3-/IDH-wildtype subgroup, recurrent alterations in EGFR (n=10) and BCOR (n=9) were identified. Additionally, we observed structural aberrations in chromosome 6 in 16/49 tumors (32.7%) across tumor types. In the pedHGG, H3-/IDH-wildtype subgroup TP53 alterations had a significant negative effect on OS. Contrary to previous studies, our representative pediatric GC study provides evidence that GC has a strong predilection to arise on the background of specific molecular features (especially pedHGG_RTK2, pedHGG_A/B, EGFR and BCOR mutations, chromosome 6 rearrangements).

8 February 2024 in EJC Paediatric Oncology
Verified
Journal Article
Open access
MEMoatasem El-Ayadi
Moatasem El-Ayadi
KDKyra Druivenga
Kyra Druivenga
TPThomas Perwein
Thomas Perwein
GNGunther Nussbaumer
Gunther Nussbaumer
FSFilippo Spreafico
Filippo Spreafico
CKChristof M. Kramm
Christof M. Kramm

25 July 2023 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
MWMaria Wiese
Maria Wiese
BPBente Pohlmeier
Bente Pohlmeier
KKKlaudia Kubiak
Klaudia Kubiak
FEFatma E. El-Khouly
Fatma E. El-Khouly
MSMaren Sitte
Maren Sitte
CKChristof Maria Kramm
Christof Maria Kramm
Pediatric high-grade gliomas (pedHGG) comprise a very poor prognosis. Thus, parents of affected children are increasingly resorting to complementary and alternative medicine (CAM), among those Boswellia extracts. However, nothing is known about the therapeutic effectiveness of their active substances, Boswellic acids (BA) in pedHGG. Thus, we aimed to investigate if the three main Boswellic acids (BA) present in Boswellia plants, alpha-boswellic acid (α-BA), beta-boswellic acid (β-BA) and 3-acetyl-11-keto-beta-boswellic acid (AKBA) hold any promising potential for treatment of affected pedHGG patients. Histone 3 (H3)-wildtype and H3.3K27M-mutant pedHGG cell lines were treated with BA, either alone or in combination with radio-chemotherapy with temozolomide. Cell viability, stemness properties, apoptosis, in ovo tumor growth and the transcriptome was investigated upon BA treatment. Interestingly, α-BA and β-BA treatment promoted certain tumor properties in both pedHGG cells. AKBA treatment reduced cell viability and colony growth accompanied by induction of slight anti-inflammatory effects especially in H3.3K27M-mutant pedHGG cells. However, no effects on apoptosis and in ovo tumor growth were found. In conclusion, besides positive anti-tumor effects of AKBA, tumor promoting effects were observed upon treatment with α-BA and β-BA. Thus, only pure AKBA formulations may be used to exploit any potential positive effects in pedHGG patients. In conclusion, the use of commercially available supplements with a mixture of different BA cannot be recommended due to detrimental effects of certain BA whereas pure AKBA formulations might hold some potential as therapeutic supplement for treatment of pedHGG patients.

6 July 2025 in EJC Paediatric Oncology
Verified
Journal Article
Open access
MKMichael Karremann
Michael Karremann
TPThomas Perwein
Thomas Perwein
Andre von BuerenAndre von Bueren
Andre von Bueren
GGGerrit H. Gielen
Gerrit H. Gielen
MBMartin Benesch
Martin Benesch
CKChristof Maria Kramm
Christof Maria Kramm

4 August 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
GNGunther Nussbaumer
Gunther Nussbaumer
MBMartin Benesch
Martin Benesch
ABAgnes Bokros
Agnes Bokros
IBInes B. Brecht
Ines B. Brecht
ISIrene Speicher
Irene Speicher
Dominik SchneiderDominik Schneider
Dominik Schneider